TUMORIN Clinical Trial
Non-Small Cell Lung Cancer (NSCLC)
N/A (Diagnostic Validation)Active
Key Facts
Indication
Non-Small Cell Lung Cancer (NSCLC)
Phase
N/A (Diagnostic Validation)
Status
Active
Company
About Nilogen Oncosystems
Nilogen Oncosystems is a private, pre-revenue biotechnology company providing a proprietary translational research platform for immuno-oncology. Its patented 3D-EXplore technology creates 'tumoroids' from minimally processed fresh patient tissue, preserving the intact tumor microenvironment (TME) and heterogeneity to better predict clinical drug response. The company offers this as a service to biopharma clients for testing cell therapies, oncolytic viruses, antibodies, and chemotherapies, and is also conducting its own clinical trial to validate the platform's predictive power.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| Idylla EGFR Mutation Assay | Biocartis | Approved |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| Macrocyclic OMNI-EGFR Inhibitor | BlossomHill Therapeutics | Phase 1 |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| Lazertinib (Leclaza) | Genosco | Approved |
| IPH5201 (anti-CD39 mAb) | Orega Biotech | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Aspyre Clinical Test for Lung | Biofidelity | Commercial |
| EGFR Mutation Detection Assay | Stilla Technologies | Assay Development/Validation |
| OX-4224 | OmRx Oncology | Phase 2 |